HD-OPM Archive
Topics › Inflammation & CRP

Preview of HORIZON (Lp(a)) and ZEUS (IL-6): improved bloodwork is not enough

Louis Nervegna · Nov 06, 2026 · ♥ 8 reactions · 2 comments · original Facebook post
Inflammation & CRPLp(a)How to read research
AI summary & key facts

Louis announces an upcoming discussion of two failed cardiology trials and shares a post arguing treatments should be judged on outcomes, not just lab numbers. In ZEUS, IL-6 and hsCRP fell but the combined risk of heart attack, stroke or CV death was not significantly reduced.

Tomorrow we are going to learn the details behind two major cardiology outcome trials that failed:

HORIZON targeting Lp(a)
ZEUS targeting IL-6 and hsCRP

Quoted from the original post:

This is why you should want to see more than improved bloodwork before calling a treatment a success.

In ZEUS, a drug lowered inflammation markers [IL-6 & hsCRP] in people with cardiovascular and kidney disease, but didn’t significantly reduce their combined risk of heart attack, stroke or cardiovascular death.

That distinction matters well beyond this trial. In health and longevity, we spend a lot of time tracking numbers. The harder question is whether changing those numbers actually improves someone’s health.

I’m watching Saturday’s (tomorrow's) American Heart Association presentation closely. The headline results are already public, but the presentation will provide more clarity.

Selected references:

#zeusHD #il6HD #hscrpHD #inflammationHD #il1betaHD

Research cited

← newer: AHA's current recommended diet is essentially the Mediterranolder: Hyperkalemia can stop the heart, so kidney disease patients →